Showing results (871-880 of 988) with videos related to
Sort By:
Pageof 99
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.Biotechnology for Biofuels|June 18, 2016
Strain and bioprocess improvement of a thermophilic anaerobe for the production of ethanol from woodChristopher D Herring, William R Kenealy, A Joe Shaw, et al.Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.Annals of the Rheumatic Diseases|April 30, 2015
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locusJohn Bowes, Sabine Loehr, Ashley Budu-Aggrey, et al.Annals of the Rheumatic Diseases|August 20, 2017
Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasisJohn Bowes, James Ashcroft, Nick Dand, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancerToni K Choueiri, Robert W Ross, Susanna Jacobus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2016
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue SarcomaChristopher W Ryan, Ofer Merimsky, Mark Agulnik, et al.Cancer|January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaWalter M Stadler, Robert A Figlin, David F McDermott, et al.The Journal of Urology|April 18, 2007
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot studyAdam S Kibel, Eli Rosenbaum, Michael W Kattan, et al.Human Molecular Genetics|November 28, 2012
Common variation at 2q22.3 (ZEB2) influences the risk of renal cancerMarc Henrion, Matthew Frampton, Ghislaine Scelo, et al.Pageof 99